Remove 2018 Remove Licensing Remove Regulations
article thumbnail

Article FDA Thank You Following a 2018 draft framework, FDA unveils long-awaited PDURS draft guidance

Agency IQ

Following a 2018 draft framework, FDA unveils long-awaited PDURS draft guidance A long-awaited draft guidance on Prescription Drug Use-Related Software (PDURS) outlines when information from digital health tools could be represented on prescription drug labeling. See AgencyIQ’s full analysis of the 2018 framework, and industry response, here.]

FDA 40
article thumbnail

Gamma delta T cells: a rising star in cancer therapy

Drug Target Review

Trends Immunol 39(6):446-459 (2018). Nat Commun 9(1):1760 (2018). Normality sensing licenses local T cells for innate-like tissue surveillance. Regulation of cutaneous malignancy by gammadelta T cells. J Front Immunol 9:1409 (2018). Davey M, Willcox C, Baker A, et al. Davey M, Willcox C, Hunter S, et al.

Therapies 105
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

ATUZAGINSTAT

New Drug Approvals

2018 ; Ding et al., According to a company press release and a poster presentation at the 2018 CTAD conference, healthy adults received 25, 50, or 100 mg COR388 or placebo every 12 hours for 10 days; AD patients took 50 mg or placebo every 12 hours for 28 days. Epub 2018 Oct 3 PubMed. Epub 2018 Jan 30 PubMed.

article thumbnail

A Final LDT Rule in April!? Will FDA be prepared?

FDA Law Blog: Biosimilars

1] Yet FDA’s conclusions about the Agency’s ability to regulate the entire laboratory industry are based on fundamentally flawed assumptions about the number of entities and tests that will be subject to FDA regulation. This is based on FDA’s reported 2018 review of the CLIA database. [2]

FDA 69
article thumbnail

Trends in Pharmaceutical Mergers and Acquisitions

DrugBank

However, ensuring that these structures comply with applicable tax laws and regulations is essential to avoid potential legal and reputational risks. This involves assessing the strength and breadth of patents, evaluating the potential for future patent challenges, and analyzing the value derived from licensing agreements and royalty streams.

article thumbnail

Hemogenyx Pharmaceuticals PLC Announces Update on CDX Antibody Development

The Pharma Data

On 14 May 2018, the Company announced a collaboration with GlobalCo to work on its CDX antibody. Market Abuse Regulation (MAR) Disclosure. Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation No 596/2014 until the release of this announcement.

article thumbnail

AbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience Portfolio

The Pharma Data

Syndesi’s unique molecules act pre-synaptically to enhance synaptic efficiency by positively modulating the function of synaptic vesicle protein 2A (SV2A), which plays a central role in regulating neurotransmission. The lead molecule, SDI-118, was discovered by UCB before being out-licensed to Syndesi as of 2018.